117 results about "Neurotransmission" patented technology

The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C_1-4 alkyl. The substituent at the 3-position of the 1-azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compounds exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the α7 nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission. Methods for preventing or treating conditions and disorders, including central nervous system (CNS) disorders, which are characterized by an alteration in normal neurotransmission, are also disclosed. Also disclosed are methods for treating inflammation, autoimmune disorders, pain and excess neovascularization, such as that associated with tumor growth.

The present invention is directed to compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.

The present invention is directed to pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl piperidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.

The present invention relates to an aryloxypropanamine containing one or more deuterium or ¹³C in place of a hydrogen or carbon, respectively. These isotopic aryloxypropanamines of the invention are inhibitors of serotonin and norepinephrine uptake and possess unique biopharmaceutical and pharmacokinetic properties compared to the responding light atom isotopologues. The invention further provides compositions comprising these isotopic aryloxypropanamines and methods of treating diseases and conditions linked to reduced neurotransmission of norepinephrine and/or serotonin. It further provides methods for using these isotopic aryloxypropanamines to accurately determine the concentration of the light atom isotopologues in biological fluids and of studying the metabolism of the light atom isotopologues.

A method for functionally identifying an epileptogenic focus in pre-surgical evaluation in affected subjects with intractable epilepsy is described, the method including the delivery of an effective dose of a botulinum neurotoxin (BoNT) to a presumptive epileptogenic focus in the disease-compromised central nervous system of a mammal, under conditions whereby the effective dose of the botulinum neurotoxin interacts with the soluble N-ethylmaleimide-sensitive factor-attachment receptor (SNARE) proteins, thus impairing neurotransmission.

A direct, non-pharmaceutical, non-invasive method of enhancing neurophysiological and musculophysiological muscle performance, muscle rehabilitation and recovery in specific target muscle(s) in users. Use of the system may provide inhibition of spastic neurotransmission tremors. The device, system, and method utilizes direct vibration stimulation of the specific target through the use and application of a fabric/nylon sleeve or wrap shaped to conform to the extremity or joint, shoulder, neck or head on which the target resides. The device applies vibrations to the target muscle group(s) at up to 100 Hz, with the vibration generating motor mechanism contained within the fabric/nylon sleeve or wrap.

The invention provides a method based on ASSEL roll shape of a technical design of a genetic neutral network and includes the following steps: (1) first, a roll shape design parameter of the ASSEL unit and a comparison table of rolling technique parameter are used for choosing input/output eigenvector and a parameter estimated model of ASSEL roll shape is established through a reasoning estimated method of the genetic neutral network; (2) the rolling technique parameter is collected on line to deduce appropriate production conditions and the roll shape characteristic parameters of different specifications; (3) the intelligent optimization of the estimated model and geometric parameter can be used for getting reasonable design roll parameter, meanwhile, the parameter can be amended manually and dynamically; (4) finally, Auto CAD software output processing parts graph can be passed. The effect of the present invention is that the characteristic parameter of the roll design is intelligently produced by the method, and the finite representative parameters in the production can be used for predicting and fitting for roll shape processing parameters and technique parameters of different specifications of products. The times of trial rolling can be reduced and the preparation period of technology and manufacture can be shortened.

Cerium oxide nanoparticles (CeONP) can be used to treat or prevent neurodegenerative diseases, including for example Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, AIDS-related dementia, ALS, progressive supranuclear palsy, and encephalitis, as well as mitochondrial diseases and diseases associated with mitochondrial damage. In particular, CeONP having an average size of about 2 nm to about 100 nm can be administered in an amount sufficient to block production of hydroxyl or superoxide radicals, block free radical production by Aβ_(1-42), block Aβ_(1-42)-induced neuronal death, block Aβ_(1-42)-induced [Ca²⁺]_i dysfunction in neurons, block Aβ_(1-42)-induced lipid peroxidation, decrease loss of dopaminergic neurotransmission, or reduce mitochondrial dysfunction in a cell. CeONP can also be effective in treating conditions involving toxic exposures to compounds that induce mitochondrial dysfunction, such as rotenone, cyanide, carbon monoxide, polychlorinated biphenyls (PCBs) and other mitochondrial toxins.

The invention relates to a combination comprising an amount of an NO donor, such as ISDN, and/or an amount of another pharmaceutical agent that enhances neurotransmission or which acts as neuroprotectants such as memantine, clomethiazole and tacrine. These compositions can be used in producing cognition and learning enhancement, whereby the invention also provides for a new method of treatment of Alzheimer's disease and related neurodegenerative disorders.

The invention relates to an iron thermal analog test material quantity control method in the field of iron researching technology. It adopts tetrahedral prototype based on element, art, organization and capability and adopts modular structure idea to establish intelligent system which has the following modules: a front handling module, a phase-changing module, an organization capacity module and an applied nodule, wherein the front handling module reads the test parameter from database needed by thermal analog test course to provide an initial condition for the subsequent course; the phase-changing module and the organization capacity module is the dynamic analog of each physical metallurgy module of the thermal analog art; the applied module looks for the best value between the network connecting authority and the network structure by establishing the neurotransmission network module to forecast the organization and the capacity of the thermal analog test.

The invention discloses a preparation method of a paliperidone amino-acid ester compound or medicinal salt thereof used for treating mental disease, wherein the structural formula of the compound is shown as a formula (I) (described in the specification). The compound can be an optical isomer and also can be a racemic mixture. The paliperidone amino-acid ester can be metabolized and converted into paliperidone (II) with pharmacological activity in vivo after being ingested in a human body, the paliperidone (II) is taken as an antagonist for neurotransmission substance to play a pesticide effect, and the paliperidone (II) is used for treating related mental diseases such as schizophrenia.

The invention belongs to the technical field of biology, and discloses a diagnostic composition for neurotransmission disorder diseases by utilizing agrin. The diagnostic composition comprises agrin or agrin mimic epitope. The composition can be used for diagnosing neurotransmission disorder diseases, and has an excellent effect and wide market prospects.